ConductScience.org, home

Paper41999193

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa-Based Regimen in Newly Diagnosed Primary CNS Lymphoma.

Wang H and 10 others. Int J Cancer, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa-Based Regimen in Newly Diagnosed Primary CNS Lymphoma. Papers, record 41999193. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41999193

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa-Based Regimen in Newly Diagnosed Primary CNS Lymphoma.
PubMed
Journal
Int J Cancer
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang HHaotian
2Li JJia
3Cao LLuminghttps://orcid.org/0000-0002-6563-6208
4Zhang YYing
5Wan XXin
6Wang XXingtonghttps://orcid.org/0000-0003-2253-1737
7Zhao YYangzhi
8Li ZZhaoxia
9Chen CChengqian
10Song YYang
11Bai OOuhttps://orcid.org/0000-0003-4066-9473

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Central Nervous System NeoplasmsMajor topic
Lymphoma, Large B-Cell, DiffuseMajor topic
Humans
Rituximab
Female
Methotrexate
Thiotepa
Middle Aged
Aged
Retrospective Studies
Male
Adult
Transplantation, Autologous
Young Adult
Progression-Free Survival
Treatment Outcome

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
YDZJ202601ZYTS602Department of Finance of Jilin ProvincePubMed

Source PubMed

Download CSV of grants

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139585484Advances in Primary Central Nervous System Lymphoma.Curr Neurol Neurosci Rep2024https://conductscience.org/library/papers/39585484PubMed
235004280Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series.Front Oncol2021https://conductscience.org/library/papers/35004280PubMed
335116520Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.Transl Cancer Res2021https://conductscience.org/library/papers/35116520PubMed
432232989Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.Br J Haematol2020https://conductscience.org/library/papers/32232989PubMed
531997308
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.
Br J Haematol2020https://conductscience.org/library/papers/31997308PubMed
637572086A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma.Cancer2023https://conductscience.org/library/papers/37572086PubMed
736453110Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience.Haematologica2023https://conductscience.org/library/papers/36453110PubMed
835096360Primary central nervous system lymphoma in the United States, 1975-2017.Ther Adv Hematol2022https://conductscience.org/library/papers/35096360PubMed
935562406Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.Leukemia2022https://conductscience.org/library/papers/35562406PubMed
1039157596Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.EJHaem2024https://conductscience.org/library/papers/39157596PubMed
1138836097Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Hemasphere2024https://conductscience.org/library/papers/38836097PubMed
1239390309Novel Therapies for Primary Central Nervous System Lymphomas.Curr Neurol Neurosci Rep2024https://conductscience.org/library/papers/39390309PubMed
1340275355PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma.J Hematol Oncol2025https://conductscience.org/library/papers/40275355PubMed
1427132696
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Lancet Haematol2016https://conductscience.org/library/papers/27132696PubMed
1531907289Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.Neurology2020https://conductscience.org/library/papers/31907289PubMed
1640935174Real-world analysis of primary central nervous system diffuse large B-cell lymphoma.Crit Rev Oncol Hematol2025https://conductscience.org/library/papers/40935174PubMed
1719767089High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.Lancet2009https://conductscience.org/library/papers/19767089PubMed
1829054815
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Lancet Haematol2017https://conductscience.org/library/papers/29054815PubMed
1940652061Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma.Leukemia2025https://conductscience.org/library/papers/40652061PubMed
2036513674Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma.Sci Rep2022https://conductscience.org/library/papers/36513674PubMed

See all 29 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41999193

GET https://conductscience.org/api/papers/v1/41999193/references?page=2